Pfizer stock weighs unusual items against higher 2026 outlook

Pfizer stock traded at 26.14 euros on Lang & Schwarz at 2:43 p.m. CET on Wednesday, November 11, 0.35 percent above the Xetra close of Tuesday, November 10. The move followed fresh investor attention on the quality of Pfizer's reported earnings after an analysis by Simply Wall St said unusual items had reduced statutory profit by US$16 billion over the twelve months through September 2026.

Unusual Items Cloud Reported Profit

The November 10 analysis said the charges made Pfizer's statutory result look weaker than its underlying earnings potential. It also cautioned that earnings per share declined over the period, leaving investors to weigh the possibility that some unusual effects will not recur against the continuing pressure on per-share performance.

The distinction matters because Pfizer reports both U.S. GAAP measures and adjusted figures. Unusual gains and losses, acquisition-related expenses, amortization, legal matters and restructuring costs can create a wide gap between the two views. Simply Wall St argued that the latest charges may not fully represent the pharmaceutical group's recurring earnings power, but the analysis does not remove the risks around execution, competition and future product demand.

New Products Offset Covid Declines

Pfizer's third-quarter release, published on November 3, showed revenue of US$16.583 billion, broadly flat from US$16.654 billion a year earlier. Reported net income fell 8 percent to US$3.242 billion, while reported diluted earnings per share declined to US$0.56 from US$0.62. Adjusted diluted earnings per share was US$0.87 in both quarters.

The company said revenue excluding Comirnaty and Paxlovid increased 7 percent operationally. Launched and acquired products grew 32 percent operationally, helped by Eliquis, Padcev, the Vyndaqel family, Nurtec and Lorbrena. Those gains offset lower demand for Covid products and a decline in the Prevnar family.

Pfizer also recorded a one-time US$650 million acquired in-process research and development charge in the quarter related to an Innovent Biologics licensing and collaboration agreement. The company said the charge reduced adjusted diluted EPS by approximately US$0.10, underscoring why reported and adjusted figures should be read together.

Higher Guidance Raises The Bar

Management raised full-year 2026 revenue guidance to US$62.0 billion to US$64.0 billion from US$60.5 billion to US$62.5 billion previously. Adjusted diluted EPS guidance was increased and narrowed to US$2.95 to US$3.05 from US$2.80 to US$3.00.

Pfizer CEO Albert Bourla pointed to commercial momentum, disciplined execution and progress in obesity, oncology, immunology and vaccines. CFO Cecile Guegan said non-Covid products delivered strong operational growth and linked the higher outlook to year-to-date performance and confidence in the business.

For investors, the central question is whether newer and acquired products can replace shrinking Covid revenue while the pipeline produces further catalysts. The higher outlook improves the near-term earnings framework, but the large unusual-item burden and falling reported earnings per share keep the focus on the durability of profits rather than on adjusted guidance alone.

Pfizer Inc. Key Facts

• Company: Pfizer Inc.
• ISIN: US7170811035
• WKN: 852009
• Ticker: PFE
• Home exchange: NYSE
• Lang & Schwarz price: 26.14 euros at 2:43 p.m. CET on November 11, 2026
• Xetra close: 26.05 euros on November 10, 2026
• Daily change: 0.35 percent above the Xetra close

Broader sentiment for U.S. equities remains relevant as investors assess healthcare earnings and interest-rate expectations through the S&P 500 market environment.

Investors can follow further company developments and analysis through More news and analyses on Pfizer stock.